Valion Bio, Inc. (NASDAQ:VBIO) ("Valion" or the "Company"), a clinical-stage biopharmaceutical company, today announced decisive changes to its executive leadership team and Board of Directors (the "Board"). These leadership transitions are intended to strengthen organizational alignment and support focused execution as Valion advances its Entolimod and other development programs and evaluates strategic opportunities. Dean Zikria, a current member of the Board, has been appointed Interim Chief Executive Officer ("CEO"). In this role, Mr. Zikria will oversee Valion's strategic priorities, including accelerating the clinical advancement of Entolimod and aggressively pursuing commercial and government partnerships.

Valion also announced that Thomas Jensen has been appointed Chair of the Board and Chair of its Compensation Committee. He succeeds Sheryle Bolton, who has stepped down from the Board and its committees. In addition, Jared Malbin has been appointed Chair of the Board's Audit Committee.

Disclaimer:This article represents the opinion of the author only. It does not represent the opinion of Webull, nor should it be viewed as an indication that Webull either agrees with or confirms the truthfulness or accuracy of the information. It should not be considered as investment advice from Webull or anyone else, nor should it be used as the basis of any investment decision.